The pharmaceutic company said it is assessing the situation to determine how production will be impacted.
The situation will certainly contribute to a problematic drug shortage that has arisen in recent years, increasing 30% from 2021 to 2022. When one drug manufacturer, Akorn Pharmaceuticals, closed its doors, that ended the production ofThe Lake Forest, Illinois-based drugmaker was responsible for producing 75 generic drugs, all of which were pulled from the market when the company closed down. In some cases, the company was the sole supplier of particular products.
New drug shortages increased by nearly 30% from 2021 to 2022, affecting 295 products at the end of last year, according to a March report from the Senate Committee on Homeland Security and Governmental Affairs. The drug shortages are affecting cancer patients who are in desperate need of chemotherapy drugs and people in intensive care units or emergency rooms who need certain generic intravenous medications, which are in tight supply.